Literature DB >> 16491302

Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29-32 weeks.

B Resch1, W Gusenleitner, W D Müller, J Haas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16491302     DOI： 10.1007/s10096-005-0082-y

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


× No keyword cloud information.
  9 in total

1.  Epidemiology of respiratory syncytial virus infection in Southern Austria.

Authors:  B Resch; W Gusenleitner; C Mandl; W Müller
Journal:  Pediatr Infect Dis J       Date:  2000-06       Impact factor: 2.129

2.  Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV database. Pediatric Investigators Collaborative Network on Infections in Canada.

Authors:  S R Arnold; E E Wang; B J Law; F D Boucher; D Stephens; J L Robinson; S Dobson; J M Langley; J McDonald; N E MacDonald; I Mitchell
Journal:  Pediatr Infect Dis J       Date:  1999-10       Impact factor: 2.129

Review 3.  Respiratory syncytial virus prophylaxis--the story so far.

Authors:  E A F Simoes; J R Groothuis
Journal:  Respir Med       Date:  2002-04       Impact factor: 3.415

4.  Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany.

Authors:  Johannes G Liese; Eva Grill; Birgit Fischer; Irmgard Roeckl-Wiedmann; David Carr; Bernd H Belohradsky
Journal:  Eur J Pediatr       Date:  2003-03-01       Impact factor: 3.183

5.  Rehospitalization in the first year of life for high-risk survivors.

Authors:  M C McCormick; S Shapiro; B H Starfield
Journal:  Pediatrics       Date:  1980-12       Impact factor: 7.124

6.  Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn.

Authors: 
Journal:  Pediatrics       Date:  1998-11       Impact factor: 7.124

7.  Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry.

Authors:  Curt Parnes; Judith Guillermin; Rolf Habersang; Peggy Nicholes; Vijay Chawla; Tammy Kelly; Judith Fishbein; Patty McRae; Mary Goessler; Antoinette Gatti; John A Calcagno; Cheryl Eki; Kristen A Harris; Joseph Joyave; Kathy McFarland; Paul Protter; Mary Sullivan; Allan Stanford; Nancy Lovett; Marisol Ortiz; Sharon Rojas; Scott Cyrus; Janell Cyrus; Stuart Cohen; Debbie Buchin; Linda Riordan; Monica Zuniga; Rupa Shah; Carmen Minard; Arden Quintin; Glenda Douglas; John van Houten; Sharyn Freutner; Stephen Chartrand; Patsy Nowatzke; Jose Romero; Torunn Rhodes; Michelle Benoit; Emmanuel Walter; Leslie Walker; Laurie DeBonnett; Mia Cross; Teresa Free; Sharman Martin; Karen Shank; Ben Guedes; Lee Ann Atkinson; George J Halpin; Kathy Rouse; Ivan Hand; Donna Geiss; James R Marshall; Lois Burleson; Jim Boland; Kelsey Seybold; Vicki Hunter; Susan Unfer; Jackie Schmucker; Margaret Gley; Michael Marcus; Patricia Thompson; Paulino Milla; Connie Young; Robert Zanni; Virginia Zinno; Alexandra Fetter-Zarzeka; Amanda Busey; Modupe A Sokunbi; Sherrie Airington; Nancy Richard; Vellore Muraligopal; Stephanie Lewis; F Thomas Weber; Beverly P Giordano; Denise Linehan; Jane Roach; Randle Davis; Andrew A Rzepka; Teri Booth; David Smeltzer; Jeanne Walsh; Emilio Arispe; Rhonda Rowley; Christopher Bolling; Tanya Botts; Kateri Haskett; Deana Raby; Evelyn Batiz; Andrew Gelfand; Lynn Farrell; Stephen Butler; Linda Colby; Peter Schochet; Julie Bentler; David Hirsch; Lisa Wilkinson; Allen Aaronson; Eleanora Bennett; Julie Wingate; Dawn Quinn; Katherine Komendowski; Marcia Deckard; Michael Frogel; Cliff Nerwen; Steven Copenhaver; Michele Prater; Jacob Wolsztein; Kristine Mackey; Marshall Benbow; Marisela Naranjo; Sandra Hensley; Cindy Hayes; Hossein Sadeghi; Sally May Lawson; Mark McCall; Karla Combs; Joel Ledbetter; Karen Sarnosky; Cathy Swafford; Michael Speer; Wendy J Barton; J W Mink; Dianne Lemm; Mark Hudak; Elizabeth Case; Judith Rowen; Sandra Fuentes; Carly Pane; Leslie Richardson; Cesar Chavarria; Deanne Cassino; Kourosh Ghaffari; Carol Carroll; Haesoon Lee; Lydia Guclu; Christopher Johnson; Valerie Blum; Marnie L Boron; Mark Sorrentino; Robert L Hirsch; Paul C Van Veldhuisen; Carol Smith
Journal:  Pediatr Pulmonol       Date:  2003-06

8.  Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group.

Authors:  J R Groothuis; E A Simoes; M J Levin; C B Hall; C E Long; W J Rodriguez; J Arrobio; H C Meissner; D R Fulton; R C Welliver
Journal:  N Engl J Med       Date:  1993-11-18       Impact factor: 91.245

9.  Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group.

Authors:  X Sáez-Llorens; E Castaño; D Null; J Steichen; P J Sánchez; O Ramilo; F H Top; E Connor
Journal:  Pediatr Infect Dis J       Date:  1998-09       Impact factor: 2.129
  9 in total
  14 in total

1.  A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice.

Authors:  Bosco A Paes; Ian Mitchell; Anna Banerji; Krista L Lanctôt; Joanne M Langley
Journal:  Can Respir J       Date:  2011 Mar-Apr       Impact factor: 2.409

2.  RSV infection among children born moderately preterm in a community-based cohort.

Authors:  Rolof G P Gijtenbeek; Jorien M Kerstjens; Sijmen A Reijneveld; Eric J Duiverman; Arend F Bos; Elianne J L E Vrijlandt
Journal:  Eur J Pediatr       Date:  2014-09-06       Impact factor: 3.183

3.  The impact of prophylaxis on paediatric intensive care unit admissions for RSV infection: a retrospective, single-centre study.

Authors:  Michelle L Butt; Amanda Symington; Marianne Janes; Louann Elliott; Susan Steele; Bosco A Paes
Journal:  Eur J Pediatr       Date:  2010-12-22       Impact factor: 3.183

4.  Prospective evaluation of clinical scoring systems in infants with bronchiolitis admitted to the intensive care unit.

Authors:  S Rödl; B Resch; N Hofer; I Marschitz; G Madler; E Eber; G Zobel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-04-21       Impact factor: 3.267

5.  Incidence of Respiratory Disease During the First Two Years of Life in Children with Hemodynamically Significant Congenital Heart Disease in Italy: A Retrospective Study.

Authors:  Giacomo Pongiglione; Alessandro Possidoni; Umberto di Luzio Paparatti; Anna Maria Costanzo; Giuliana Gualberti; Marco Bonvicini; Alessandro Rimini; Gabriella Agnoletti; Maria Pia Calabrò; Marco Pozzi; Roberto Tumbarello; Patrizia Salice; Patrizio Fiorini; Maria Giovanna Russo; Ornella Milanesi
Journal:  Pediatr Cardiol       Date:  2016-08-29       Impact factor: 1.655

Review 6.  Prematurity and the burden of influenza and respiratory syncytial virus disease.

Authors:  Bernhard Resch; Stefan Kurath-Koller; Monika Eibisberger; Werner Zenz
Journal:  World J Pediatr       Date:  2015-11-19       Impact factor: 2.764

7.  Respiratory syncytial virus infection in children with neuromuscular impairment.

Authors:  Arne Simon; Julia Prusseit; Andreas Müller
Journal:  Open Microbiol J       Date:  2011-12-30

8.  Epidemiology of respiratory syncytial virus infection in preterm infants.

Authors:  Bernhard Resch; Stefan Kurath; Paolo Manzoni
Journal:  Open Microbiol J       Date:  2011-12-30

Review 9.  Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective.

Authors:  Nusrat Homaira; William Rawlinson; Thomas L Snelling; Adam Jaffe
Journal:  Int J Pediatr       Date:  2014-12-04

10.  Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV).

Authors:  Joseph M Geskey; Neal J Thomas; Gretchen L Brummel
Journal:  Biologics       Date:  2007-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.